Country | Estimated G6PDd for common variants (mostly A −) | PQ use | PQ as DOT? | G6PD testing required for PQ administration |
---|---|---|---|---|
Brazil | >3–7% [132] 0–12.9% [133] | P. falciparum and P. vivax | No | No-currently under consideration and expected to be recommended when possible with follow-up of possible PQ-induced haemolysis G6PDd cases to be treated with PQ at 0.75 mg/kg/week for 8 weeks |
Colombia | >3–7% [132] 1.4–15.4% [133] 6.56% [135] | P. vivax | No | No |
Peru | >0–1% [132] 0–0.7% [133] | P. falciparum (since 2015) and P. vivax | Yes | No |
Venezuela | >7–10% [132] 0–3.5% [133] 3.6% [134] | P. falciparum and P. vivax | No | No |